/organisation/dyax-corporation-nasdaq-shire-group-cambridge-massachusetts-federal-2001-6270.html
 
 
 
 
 
 

Advertisement

Picture EBD Group BIO-Europe 2018 Copenhagen Denmark Partnerships 600x60px
Organisation › Details

Dyax Corporation (Nasdaq: DYAX)

Dyax is focused on advancing novel biotherapeutics for unmet medical needs, with an emphasis on oncology and inflammatory indications. Dyax utilizes its proprietary drug discovery technology to identify antibody, small protein and peptide compounds for clinical development.

Dyax's lead product candidate is DX-88, a recombinant small protein that is currently in clinical trials for its therapeutic potential in two separate indications. Dyax has successfully completed three Phase 2 trials and a Phase 3 trial of DX-88 for the treatment of hereditary angioedema (HAE). A confirmatory study, known as EDEMA4, is planned and expected to begin in the first quarter of 2007. DX-88 has orphan drug designation in the U.S. and E.U., as well as Fast Track designation in the U.S. for the treatment of acute attacks of HAE.

Additionally, Dyax has successfully completed a Phase 1/2 trial of DX-88 for the prevention of blood loss during on-pump coronary artery bypass graft (CABG) procedures. Dyax is initiating a Phase 2 trial for further development of DX-88 in on-pump cardiothoracic surgery (CTS), including CABG and heart valve replacement or repair procedures. Dyax identified DX-88 and other compounds in its pipeline using its patented phage display technology, which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. Dyax leverages this technology broadly with over 70 revenue-generating licenses and collaborations for therapeutic discovery, as well as in non-core areas such as affinity separations, diagnostic imaging, and research reagents. Dyax is headquartered in Cambridge, Massachusetts, with antibody discovery facilities in Liege, Belgium. For online information about Dyax Corp., please visit www.dyax.com. *

 

  Group Shire (Group)
Product Industry phage display technology
     
  Street 300 Technology Square
  City 02139 Cambridge, MA
  Tel +1-617-225-2500
    Address record changed: 2018-07-24
     
Basic data Employees n. a.
  Currency USD
  Annual sales 19,860,000 (sales, net (2005) 2005-12-31)
  Profit -30,940,000 (2005-12-31)
  Cash 50,660,000 (2005-12-31)
     
    * Document for �About Section�: 
     
   
Record changed: 2017-09-02

Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October iito 600x60px

More documents for Shire (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px




» top